Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer. Issue 7 (20th May 2019)

• Record Type: Journal Article
• Authors: Kleiblova, Petra; Stolarova, Lenka; Krizova, Katerina; Lhota, Filip; Hojny, Jan; Zemankova, Petra; Havranek, Ondrej; Vocka, Michal; Cerna, Marta; Lhotova, Klara; Borecka, Marianna; Janatova, Marketa; Soukupova, Jana; Sevcik, Jan; Zimovjanova, Martina; Kotlas, Jaroslav; Panczak, Ales; Vesela, Kamila; Cervenkova, Jana; Schneiderova, Michaela; Burocziova, Monika; Burdova, Kamila; Stranecky, Viktor; Foretova, Lenka; Machackova, Eva; Tavandzis, Spiros; Kmoch, Stanislav; Macurek, Libor; Kleibl, Zdenek
• Is Part Of: International journal of cancer. Volume 145:Issue 7(2019)
• Page Start: 1782
• Page End: 1797
• Publication Date: 2019-05-20
• Subjects: breast cancer -- ovarian cancer -- germline mutations -- CHEK2 -- VUS -- KAP1 -- functional assay; Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.32385
• Languages: English
• ISSNs: 0020-7136

Abstract

Abstract : Germline mutations in checkpoint kinase 2 ( CHEK2 ), a multiple cancer‐predisposing gene, increase breast cancer (BC) risk; however, risk estimates differ substantially in published studies. We analyzed germline CHEK2 variants in 1, 928 high‐risk Czech breast/ovarian cancer (BC/OC) patients and 3, 360 population‐matched controls (PMCs). For a functional classification of VUS, we developed a complementation assay in human nontransformed RPE1‐ CHEK2 ‐knockout cells quantifying CHK2‐specific phosphorylation of endogenous protein KAP1. We identified 10 truncations in 46 (2.39%) patients and in 11 (0.33%) PMC ( p = 1.1 × 10 −14 ). Two types of large intragenic rearrangements (LGR) were found in 20/46 mutation carriers. Truncations significantly increased unilateral BC risk (OR = 7.94; 95%CI 3.90–17.47; p = 1.1 × 10 −14 ) and were more frequent in patients with bilateral BC (4/149; 2.68%; p = 0.003), double primary BC/OC (3/79; 3.80%; p = 0.004), male BC (3/48; 6.25%; p = 8.6 × 10 −4 ), but not with OC (3/354; 0.85%; p = 0.14). Additionally, we found 26 missense VUS in 88 (4.56%) patients and 131 (3.90%) PMC ( p = 0.22). Using our functional assay, 11 variants identified in 15 (0.78%) patients and 6 (0.18%) PMC were scored deleterious ( p = 0.002). Frequencies of functionally intermediate and neutral variants did not differ between patients and PMC. Functionally deleterious CHEK2 missense variants significantly increased BC risk (OR = 3.90; 95%CI 1.24–13.35; p = 0.009) and marginally OC risk (OR = 4.77; 95%CI 0.77–22.47; p = 0.047); however, carriers low frequency will require evaluation in larger studies. Our study highlights importance of LGR detection for CHEK2 analysis, careful consideration of ethnicity in both cases and controls for risk estimates, and demonstrates promising potential of newly developed human nontransformed cell line assay for functional CHEK2 VUS classification. Abstract : What's new? The tumor suppressor gene checkpoint kinase 2 ( CHEK2 ) encodes a protein that serves an important role in DNA repair. However, CHEK2 is also vulnerable to mutations that potentially impact breast cancer risk. Using a functional cell‐based assay, the authors of the present study show that truncating and missense CHEK2 variants are associated with risk of both breast and ovarian cancer. One‐third of truncating mutations involved large genomic rearrangements. In addition, CHEK2 mutations predisposed women to specific breast cancer types, and CHEK2 mutation carriers with a family history of cancer were at increased risk of developing second primary cancers.